Abbott India Ltd.

“Abbott India is a structurally sound, asset-light branded pharma compounder with a near-unassailable position in thyroid therapy (Thyronorm), zero net debt, 34% ROE, and consistent double-digit EPS growth — but the business compounds at 8-10% organically, and at 38x trailing P/E the price already captures all of that quality with nothing left for the investor. The structural ceiling — DPCO pricing limits, parent-dependent pipeline, no scalable reinvestment opportunities, royalty leakage to Abbott Laboratories — means returns from here are a function of multiple, not business improvement. Minority shareholders face governance subordination but not fraud. The risk of permanent capital loss is low; the risk of decade-long mediocre returns is high. Wait for 25-28x earnings (~INR 18,000-21,000) before initiating.”